Phase 4 N=16 Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
Hemophilia A
Primary: ITI Success — 1; 2; 6; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=428 Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation
Intubation Complication
Primary: Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI — 138.04; 132.39; 139.09; 130.09 mmHg
Phase 4 N=43 Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine
Hemorrhage · Healthy
Primary: Cumulative Stress Index — 635; 649 mmHg x minutes
Phase 4 N=10 Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
Attention-Deficit/Hyperactivity Disorder
Primary: Cmax — 8.07; 10.09; 15.45 ng/mL
Phase 4 N=562 AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
Post-Operative Atrial Fibrillation
Primary: Number of Perioperative Complications Associated With AtriClip Placement — 0 perioperative complications reported
Phase 4 N=79 Trial Comparing Intrathecal Morphine With Placebo In Patients Undergoing Robotic Cardiac Surgery
Pain
Primary: Postoperative Morphine Consumption — 59; 28 Miligram
Phase 4 N=70 Narcotics vs NSAIDs for Post-operative Analgesia in Outpatient Rhinoplasty
Rhinoplasty · Non-steroidal Ant Inflammatory Drugs · Opioid Use
Primary: Average Pain Score — 2.54; 3.14 score on a scale
Phase 4 N=10 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy
Idiopathic Angioedema
Primary: Mean 7-day Angioedema Activity Score (AAS7) — 2.8; 1.6; 0.69; 0.20 score on a scale
Phase 4 N=185 Impact of Liraglutide 3.0 on Body Fat Distribution
Obesity, Visceral · Cardiovascular Diseases · Fat Disorder
Primary: Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI — 12.49; 1.63 percentage of reduction in VAT
Phase 4 N=213 A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 3 Hours (AUC0-3h) After 4 Weeks of Treatment. — 0.250; -0.086…
Phase 4 N=75 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
Multiple Sclerosis
Primary: The Primary Outcome Measure is the Number of "Combined Active Lesions" (CAL) by Monthly MRI at the Conclusion of the Study. — 0.63; 0.58 Average number of lesions per…
Phase 4 N=27 Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI
Spinal Cord Injuries · Neuropathic Pain
Primary: Neuropathic Pain — 13.3; 15.6 units on a scale — p=0.67
Phase 4 N=83 Effects of Intranasal Oxytocin on Cigarette Smoking
Nicotine Dependence · Tobacco Smoking
Primary: Smoking Lapse Analogue Task (Delay Score) — 11.5; 10.9 minutes
Phase 4 N=204 Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
Acute Coronary Syndrome (ACS)
Primary: Mean Change From Baseline to Week 4 in P2Y12 Reaction Units During Period 1 — -18.2 P2Y12 reaction unit
Phase 4 N=278 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Colitis, Ulcerative
Primary: Percentage of Participants Achieving Mucosal Healing at Week 30 — 18.9; 14.5 percentage of participants — p==0.401